Drug Firm Caught in 'Treat by Race' Row New Heart Medicine Will Target Black Patients
Linked as:
Summary
THE world's first race-specific drug which has been developed for the exclusive treatment of black cardiac patients is being considered for approval despite ethical questions over its appropriateness.
Its manufacturer defended the decision to seek a licence for its use exclusively on black people because it claims it is significantly more effective when administered to black patients.See the full content of this document
Extract
Drug Firm Caught in 'Treat by Race' Row New Heart Medicine Will Target Black Patients
Clinical trials have found that the drug, BiDil, improves survival by 47% in black cardiac patients compared with just 15% i...
See the full content of this document
Sponsored links
